

MacroGenics, Inc. Investor Relations Department 9640 MEDICAL CENTER DRIVE Rockville, MD 20850 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: MGNX	
Last Trade:	15.52
Trade Time:	4:00 PM ET Aug 18, 2017
Change:	-0.31 🖶 (-1.958%)
Day Range	15.48 - 15.80
52-Week Range	14.36 - 32.68
Volume	283,898

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

MacroGenics is a clinicalstage biopharmaceutical company focused on discovering and developing innovative monoclonal antibodybased therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibodybased technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceu... (more)

Stock Performance



Press Releases [View all]

Aug 9, 2017

MacroGenics to Present at the Wedbush PacGrow Healthcare Conference

Aug 2, 2017

MacroGenics Provides Update on Corporate
Progress and Second Quarter 2017 Financial
Results

Jul 26, 2017

MacroGenics Announces Date of Second
Quarter 2017 Financial Results Conference
Call

Jul 17, 2017

Phase 1 Data for Flotetuzumab,

MacroGenics' CD123 x CD3 DART®

Molecule, Accepted for Oral Presentation at

ESMO Congress 2017

Jun 17, 2017

MacroGenics Presents Updated Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2017)

Financials [View all]

Second Quarter Financial Results

Feb 28, 2017

Annual Report (10-K)

Apr 4, 2017

Proxy Statement (DEF 14A)

Aug 2, 2017

Quarterly Report (10-Q)

May 3, 2017

Quarterly Report (10-Q)

Nov 2, 2016

Quarterly Report (10-Q)